• 1
    Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the ncic clinical trials group. J Clin Oncol. 2011;29:3278-3285.
  • 2
    Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
  • 3
    Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822-3829.
  • 4
    Ihle NT, Lemos R Jr, Wipf P, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009;69:143-150.
  • 5
    Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14:1351-1356.
  • 6
    Torvik J, Wik E, Stefansson IM, et al. Stathmin over expression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res. 2011;17:3368-3377.
  • 7
    Emons G, Heyl W. Hormonal treatment of endometrial cancer. J Cancer Res Clin Oncol. 2000;126:619-623.
  • 8
    Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736-1744.
  • 9
    Swenerton KD, White GW, Boyes DA. Treatment of advanced endometrial carcinoma with tamoxifen. N Engl J Med. 1979;301:105.
  • 10
    Bellone S, Shah HR, McKenney JK, et al. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol. 2008;199:e7-e10.
  • 11
    Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004;14:650-658.
  • 12
    Deppe G, Malviya VK, Malone JM, Christensen CW, Saunders D. Treatment of recurrent and metastatic endometrial cancer with cisplatin and doxorubicin. Eur J Gynaecol Oncol. 1994;15:263-266.
  • 13
    Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159-2166.
  • 14
    Salvesen HB, Stefansson I, Kretzschmar EI, et al. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol. 2004;25:1615-1623.
  • 15
    Mackay HJ, Gallinger S, Tsao M, et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC-CTG). Eur J Cancer. 2010;46:1365-1373.
  • 16
    Lu KH, Wu W, Dave B, et al. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res. 2008;14:2543-2550.
  • 17
    Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res. 2006;12:5932-5935.
  • 18
    Janju P, Wheler JJ, Westeni S, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012;30:777-782.
  • 19
    Mackay H, Welch S, Tsao MS, et al. Phase II trial of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND192 [Abstract]. J Clin Oncol. 2011;29(suppl 15): abstract 5013.
  • 20
    Dowling RJO, Niraula S, Stambolic V, Goodwin P. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48:R31-R43.
  • 21
    Andersen SS. Spindle assembly and the art of regulating microtubule dynamics by MAPs and Stathmin/Op18. Trends Cell Biol. 2000;10:261-267.
  • 22
    Marklund U, Larsson N, Gradin HM, Brattsand G, Gullberg M. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics EMBO J. 1996;15:5290-5298.
  • 23
    Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009;106:4834-4839.
  • 24
    McConechy MK, Ding J, Cheang MCU, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228:20-30.
  • 25
    Oda K, Stokoe D, Taketani Y, et al. High frequency of co-existing mutations of PIK3CA and PTEN genes in endometrial cancer Cancer Res. 2005;65:10669-10673.
  • 26
    Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135.
  • 27
    Vandenput I, Trovik J, Leunen K, et al. Evolution in endometrial cancer: evidence from an immunohistochemical study. Int J Gynecol Cancer. 2011;21:316-322.
  • 28
    McAlpine JN, Bashashati A, Ha G, et al.Intratumoral heterogeneity in high-grade serous cancers: defining evolution of the somatic mutational landscape across spatially and temporally selected samples. Proceedings of the 14th Biennial Meeting of the International Gynecologic Cancer Society, Vancouver, Canada; October 13-16, 2012; p E73.
  • 29
    Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-1417.
  • 30
    Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
  • 31
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.